Wrinkles - Pipeline Insight, 2024

Wrinkles - Pipeline Insight, 2024

DelveInsight’s, “Wrinkles - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Wrinkles pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Wrinkles Understanding

Wrinkles: Overview

Wrinkles are folds or creases that appear on the face and body as the skin loses elasticity and the amount of collagen in the dermis, or middle layer of the skin, and the quantity of fat in the subcutaneous or deepest layer of the skin decrease over time. In addition to natural aging processes, wrinkles appear on the face as a result of smoking cigarettes or exposure to ultraviolet radiation. The amount of wrinkles an individual will have in later life is further influenced by biological, genetic, and environmental factors as well as by his or her weight, with heavier individuals often tending to have fewer wrinkles than those who are slimmer. While some people begin to develop wrinkles as early as their 20s, others do not have any wrinkles until much later in life. Women tend to develop more wrinkles than men because they have fewer sweat and sebaceous glands, not as many blood vessels, and different muscle structures that collectively make them more vulnerable to facial creasing.

""Wrinkles - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wrinkles pipeline landscape is provided which includes the disease overview and Wrinkles treatment guidelines. The assessment part of the report embraces, in depth Wrinkles commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wrinkles collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Wrinkles R&D. The therapies under development are focused on novel approaches to treat/improve Wrinkles.

Wrinkles Emerging Drugs Chapters

This segment of the Wrinkles report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wrinkles Emerging Drugs

• ET-01: Eirion Therapeutics

ET-01 is a topical botulinum product being developed with the goal of avoiding the pain, bleeding and bruising that can be associated with the injection of commercially available botulinum products. ET-01 employs a nanoemulsion transdermal delivery technology essential for a large molecule such as botulinum to penetrate into the skin. ET-01 is administered in the physician’s office using a proprietary two-step process that is completed in minutes: Step 1: A pre-conditioning procedure (“microporation”) creates temporary micropores in the skin to maximize the bioavailability of ET-01. Step 2: ET-01 is applied to and then fully rubbed into the skin by a health professional using a gloved finger.

• KB301: Krystal Biotech

KB301 is designed to restore collagen locally by enabling cells to produce full-length human type III collagen (COL3A1), thereby fundamentally addressing the biology of aging skin.

Further product details are provided in the report……..

Wrinkles: Therapeutic Assessment

This segment of the report provides insights about the different Wrinkles drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Wrinkles

There are approx. 10+ key companies which are developing the therapies for Wrinkles. The companies which have their Wrinkles drug candidates in the most advanced stage, i.e. phase II include, Eirion Therapeutics.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Wrinkles pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Wrinkles: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Wrinkles therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wrinkles drugs.

Wrinkles Report Insights

• Wrinkles Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Wrinkles Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Wrinkles drugs?
• How many Wrinkles drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Wrinkles?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Wrinkles therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wrinkles and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eirion Therapeutics
• Krystal Biotech
• Topokine Therapeutics
• Medytox
• Galderma R&D
• Daewoong Pharmaceuticals

Key Products

• ET-01
• KB301
• TAT 4
• Meditoxin
• QM1114
• Prabotulinumtoxin A